Keywords: |
adult; cancer chemotherapy; clinical article; aged; drug efficacy; antineoplastic agents; melanoma; phase 2 clinical trial; leukopenia; nausea; stomatitis; vomiting; gastrointestinal toxicity; daunorubicin; idarubicin; drug therapy; adverse drug reaction; mouth; therapy; intravenous drug administration; hematologic diseases; middle age; bone marrow depression; drug evaluation; intoxication; human; male; female; priority journal; support, non-u.s. gov't; support, u.s. gov't, p.h.s.; blood and hemopoietic system
|